President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

DAVOS: Prime Minister Datuk Seri Anwar Ibrahim held high-­level meetings with business leaders from six multinational ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing, Ascentage (AAPG) ...

AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

UK’s former vaccine tsar says immunocompromised people were ‘de-prioritised’ in a ‘two-tier’ therapeutic rollout strategy ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...